Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Hosted on MSN4d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback